Shire defends high prices of orphan drugs
This article was originally published in SRA
Executive Summary
Shire has defended the high prices charged for orphan drugs, claiming that while the costs of developing an orphan drug may be the same as developing any other drug, the capital costs associated with orphan drug development are "not so obvious", and the challenges to development are more numerous.